View ValuationThis company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsRenovacor 향후 성장Future 기준 점검 0/6핵심 정보-93.6%이익 성장률-35.45%EPS 성장률Biotechs 이익 성장24.9%매출 성장률90.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트n/a최근 향후 성장 업데이트Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.모든 업데이트 보기Recent updates공시 • Dec 02Renovacor Requests NYSE to Remove its Shares from ListingOn December 1, 2022 (the Closing Date"), Rocket Pharmaceuticals, Inc. ("Rocket" or Parent"), completed the previously announced acquisition of Renovacor, Inc., a Delaware corporation ("the Company," Renovacor") pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022 (the Merger Agreement"), by and among Rocket, Renovacor, Zebrafish Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Rocket (Merger Sub I"), and Zebrafish Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Rocket (Merger Sub II"). On December 1, 2022, in connection with the consummation of the Mergers, the Company (i) notified The New York Stock Exchange American LLC (the NYSE") of the consummation of the Mergers and (ii) requested that the NYSE remove Company Shares and the Company Public Warrants from listing and file a Form 25 with the SEC to report the delisting of the Company Shares and Company Public Warrants from the NYSE. Upon effectiveness of the Form 25, the Company intends to file with the SEC a Certification and Notice of Termination on Form 15 with the SEC to suspend Renovacor's reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended.Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Sep 22Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million on September 19, 2022. Under the terms of the transaction, Renovacor shareholders will receive approximately 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and are expected to own approximately 4.6% percent of Rocket equity on a fully diluted basis immediately following the closing of the transaction. The exchange ratio implies an equity deal value of approximately $53 million based on fully diluted shares outstanding and the acceleration and vesting of all earnout shares, or $2.60 per share of Renovacor. The exchange ratio is subject to adjustment based on Renovacor net cash at closing. Rocket shall pay a termination fee of $1.74 million to Renovacor and Renovacor shall pay a termination fee of $1.74 million to Rocket. RTW Investments, LP, a significant shareholder of both Rocket and Renovacor, has entered into a voting agreement with Renovacor, pursuant to which they have agreed, among other things, and subject to the terms and conditions of the agreement. The deal is subject to approval by Renovacor and Rocket shareholders, receipt of any required customary regulatory approvals, the required approvals by Rocket’s and Renovacor’s stockholders, the Rocket Shares to be issued in the First Merger being approved for listing on Nasdaq as of the closing, the Registration Statement having become effective, the waiting period under the HSR Act shall have expired or been terminated and the satisfaction of other customary closing conditions. The boards of directors of both companies have unanimously approved the transaction, which is currently expected to close by the first quarter of 2023. SVB Securities is serving as exclusive financial advisor and fairness opinion provider and John T. Haggerty, William D. Collins and Sarah Ashfaq of Goodwin Procter LLP is serving as legal counsel to Rocket. Wells Fargo Securities is serving as exclusive financial advisor and fairness opinion provider and Rachael Bushey and Jennifer Porter of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Renovacor.공시 • Jul 13Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic CardiomyopathyRenovacor, Inc. announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI). The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration. The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM. The new program is being developed as an AAV-based gene therapy to treat potentially life-threatening arrhythmias associated with the disease by restoring gap junction protein trafficking and gap junction communication between heart muscle cells. The program will be developed for the three largest genetic segments of ACM: plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmoplakin (DSP) associated ACM. Currently available treatment options do not address the trafficking defects central to each of the these genetically-driven forms of ACM. The collaboration leverages positive proof-of-concept data generated in a genetic mouse model of ACM that was performed by the Shaw Lab, led by Robin Shaw, M.D., Ph.D., Professor of Medicine at the University of Utah and Director of the CVRTI. These data demonstrate restoration of gap junction trafficking to the intercalated disc and a significant reduction in premature ventricular contractions (PVCs). PVCs are a hallmark of ACM and key drivers of potentially lethal ventricular arrhythmias. Arrhythmogenic cardiomyopathy (ACM) is a heritable heart muscle disorder that can affect the left and right ventricle. It is characterized by a heightened risk of potentially lethal ventricular arrhythmias, fibrofatty replacement of myocardial tissue, and in some patients, heart failure.(1,2) It is recognized as a disease of the desmosome, with well-defined genetic drivers. The prevalence of ACM is estimated to range from 1 case in 1,000 persons to 1 case in 5,000, with an average age of diagnosis of approximately 30 years.(1-3) Current treatment options aim to prevent potentially life-threatening arrhythmias and progression to end-stage disease, but they do not target the underlying genetics or disease biology and, as such, patients can continue to experience serious breakthrough events.공시 • Jun 26+ 1 more updateRenovacor Appoints Wendy Dicicco as the Chief Financial OfficerOn June 3, 2022, the Renovacor, Inc. reported that its Board of Directors (the “Board”) had appointed Wendy DiCicco as the Company’s Chief Financial Officer. Under the CFO Agreement, Ms. DiCicco will provide services to the Company as its Chief Financial Officer in a non-employee capacity, effective as of June 17, 2022 (Effective Date).공시 • Jun 05+ 1 more updateRenovacor, Inc. Announces CFO ChangesOn May 30, 2022, Fred Driscoll, the Chief Financial Officer of Renovacor, Inc. notified the Company of his decision to resign effective as of June 17, 2022 (the “Effective Date”). Mr. Driscoll resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company’s financial or accounting operations, policies or practices. On June 2, 2022, the Board of Directors (the “Board”) of the Company appointed Wendy DiCicco, the Company’s former Interim Chief Financial Officer, as Chief Financial Officer, effective as of the Effective Date. Ms. DiCicco will assume the duties of the principal financial officer of the Company as of the Effective Date. Ms. DiCicco served as the Company’s Interim Chief Financial Officer from September 2019 to March 2022, after which she continued to serve in a consulting capacity. In addition, since November 2018 she has served as an executive board advisory consultant for Board Advantage, LLC. Prior to this time, she was the Chief Operating and Financial Officer of Centinel Spine from August 2017 to October 2018. She previously served as President and Chief Operating Officer of Camber Spine Technologies from November 2014 to July 2017, and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Ms. DiCicco has served on the boards of directors of SWK Holdings since February 2022, Sincerus Pharmaceuticals since July 2021, Imvax, Inc. since July 2020, ExpressCells since March 2020 and EyePoint Pharmaceuticals since July 2019. She previously served on the boards of directors of II-VI, Inc. from 2006 until August 2017 as well as the boards of CannaPharma Rx and Syncardia Systems. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA.공시 • Jun 02Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of CardiologyRenovacor, Inc. announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. REN-001 is an AAV-based gene therapy designed to directly address the underlying cause of BAG3-associated dilated cardiomyopathy (BAG3-DCM) by using a validated AAV9 capsid to deliver a functional copy of the BAG3 gene to cardiac tissue. In the pilot Yucatan pig study featured in JACC: BTS, low doses (<1e13 vector genome (vg) per kilogram (kg)) of REN-001 delivered locally to the heart using RCSI resulted in each evaluated cardiomyocyte containing, on average, at least one copy of the delivered BAG3 gene (i.e., vector copy number threshold =1). The study also demonstrated diffuse transduction patterns across multiple regions of the heart and documented the presence of vector mRNA /transcript. Additionally, all animals tolerated the procedure without evidence of heart injury (e.g., arrythmia, presence of myocardial scar, or coronary sinus injury at necropsy). The pilot Yucatan pig study published in JACC: BTS included three dose groups. Group A evaluated a 1.46e12 vg/kg dose, Group B evaluated a 3.45e12 vg/kg dose and Group C evaluated a 7.58e12 vg/kg dose (based on median pig weights for each group). Levels of vector genomes and corresponding RNA transcripts were quantified.Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공시 • Apr 15Renovacor, Inc., Annual General Meeting, May 25, 2022Renovacor, Inc., Annual General Meeting, May 25, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect three director nominees that are set forth in the attached 2022 Annual Meeting Proxy Statement, or the Proxy Statement, to serve as Class I directors, whose term will expire in 2025; to ratify the appointment of Ernst & Young LLP, or EY, as independent registered public accounting firm for the 2022 fiscal year; and to transact any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.공시 • Mar 29Renovacor, Inc. Appoints Fred Driscoll as Chief Financial OfficerRenovacor, Inc. announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). Mr. Driscoll joins Renovacor with over 25 years of executive experience in the biotech industry. He most recently served as the CFO of Flexion Therapeutics (Flexion), where he led the company through a successful $75 million initial public offering in 2014 and subsequently raised an additional $450 million in capital for the company.Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board & Director Anne Prener was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.이익 및 매출 성장 예측NYSEAM:RCOR - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2024N/AN/AN/AN/A112/31/2023N/A-51N/AN/A412/31/2022N/A-26N/AN/A49/30/2022N/A-13-31-30N/A6/30/2022N/A-6-28-28N/A3/31/2022N/A-6-22-22N/A12/31/2021N/A-14-16-16N/A9/30/2021N/A-14-10-10N/A6/30/2021N/A-7-6-6N/A3/31/2021N/A-4-4-4N/A12/31/2020N/A-3-3-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: RCOR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: RCOR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: RCOR 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: RCOR 은(는) 내년에 수익이 없을 것으로 예상됩니다.고성장 매출: RCOR 은(는) 내년에 수익이 없을 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: RCOR의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2022/12/01 18:12종가2022/11/30 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Renovacor, Inc.는 3명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jack AllenBairdYun ZhongBTIGYevgeniya LivshitsChardan Capital Markets, LLC
Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.
공시 • Dec 02Renovacor Requests NYSE to Remove its Shares from ListingOn December 1, 2022 (the Closing Date"), Rocket Pharmaceuticals, Inc. ("Rocket" or Parent"), completed the previously announced acquisition of Renovacor, Inc., a Delaware corporation ("the Company," Renovacor") pursuant to the Agreement and Plan of Merger, dated as of September 19, 2022 (the Merger Agreement"), by and among Rocket, Renovacor, Zebrafish Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Rocket (Merger Sub I"), and Zebrafish Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Rocket (Merger Sub II"). On December 1, 2022, in connection with the consummation of the Mergers, the Company (i) notified The New York Stock Exchange American LLC (the NYSE") of the consummation of the Mergers and (ii) requested that the NYSE remove Company Shares and the Company Public Warrants from listing and file a Form 25 with the SEC to report the delisting of the Company Shares and Company Public Warrants from the NYSE. Upon effectiveness of the Form 25, the Company intends to file with the SEC a Certification and Notice of Termination on Form 15 with the SEC to suspend Renovacor's reporting obligations under Sections 13 and 15(d) of the Securities Exchange Act of 1934, as amended.
Price Target Changed • Nov 16Price target decreased to US$11.53Down from US$14.20, the current price target is an average from 3 analysts. New target price is 252% above last closing price of US$3.28. The company is forecast to post a net loss per share of US$1.55 next year compared to a net loss per share of US$1.41 last year.
Board Change • Nov 16High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Sep 22Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million.Rocket Pharmaceuticals, Inc. (NasdaqGM:RCKT) entered into a definitive agreement to acquire Renovacor, Inc. (NYSEAM:RCOR) from RTW Investments, LP and others for $46.7 million on September 19, 2022. Under the terms of the transaction, Renovacor shareholders will receive approximately 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and are expected to own approximately 4.6% percent of Rocket equity on a fully diluted basis immediately following the closing of the transaction. The exchange ratio implies an equity deal value of approximately $53 million based on fully diluted shares outstanding and the acceleration and vesting of all earnout shares, or $2.60 per share of Renovacor. The exchange ratio is subject to adjustment based on Renovacor net cash at closing. Rocket shall pay a termination fee of $1.74 million to Renovacor and Renovacor shall pay a termination fee of $1.74 million to Rocket. RTW Investments, LP, a significant shareholder of both Rocket and Renovacor, has entered into a voting agreement with Renovacor, pursuant to which they have agreed, among other things, and subject to the terms and conditions of the agreement. The deal is subject to approval by Renovacor and Rocket shareholders, receipt of any required customary regulatory approvals, the required approvals by Rocket’s and Renovacor’s stockholders, the Rocket Shares to be issued in the First Merger being approved for listing on Nasdaq as of the closing, the Registration Statement having become effective, the waiting period under the HSR Act shall have expired or been terminated and the satisfaction of other customary closing conditions. The boards of directors of both companies have unanimously approved the transaction, which is currently expected to close by the first quarter of 2023. SVB Securities is serving as exclusive financial advisor and fairness opinion provider and John T. Haggerty, William D. Collins and Sarah Ashfaq of Goodwin Procter LLP is serving as legal counsel to Rocket. Wells Fargo Securities is serving as exclusive financial advisor and fairness opinion provider and Rachael Bushey and Jennifer Porter of Troutman Pepper Hamilton Sanders LLP is serving as legal counsel to Renovacor.
공시 • Jul 13Renovacor Announces Pipeline Expansion with New Research Program for Multiple Genetic Segments of Arrhythmogenic CardiomyopathyRenovacor, Inc. announced it has expanded its pipeline to advance an AAV gene therapy program as a potential precision therapy for three genetic segments of arrhythmogenic cardiomyopathy (ACM). To accelerate this new program, Renovacor has entered into a research collaboration with the University of Utah’s Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI). The terms of the research agreement grant Renovacor an option for an exclusive license to inventions generated from the collaboration. The research collaboration will focus on a protein discovered by University of Utah scientists that has the potential to address multiple genetic segments of ACM. The new program is being developed as an AAV-based gene therapy to treat potentially life-threatening arrhythmias associated with the disease by restoring gap junction protein trafficking and gap junction communication between heart muscle cells. The program will be developed for the three largest genetic segments of ACM: plakophilin-2 (PKP2), desmoglein-2 (DSG2), and desmoplakin (DSP) associated ACM. Currently available treatment options do not address the trafficking defects central to each of the these genetically-driven forms of ACM. The collaboration leverages positive proof-of-concept data generated in a genetic mouse model of ACM that was performed by the Shaw Lab, led by Robin Shaw, M.D., Ph.D., Professor of Medicine at the University of Utah and Director of the CVRTI. These data demonstrate restoration of gap junction trafficking to the intercalated disc and a significant reduction in premature ventricular contractions (PVCs). PVCs are a hallmark of ACM and key drivers of potentially lethal ventricular arrhythmias. Arrhythmogenic cardiomyopathy (ACM) is a heritable heart muscle disorder that can affect the left and right ventricle. It is characterized by a heightened risk of potentially lethal ventricular arrhythmias, fibrofatty replacement of myocardial tissue, and in some patients, heart failure.(1,2) It is recognized as a disease of the desmosome, with well-defined genetic drivers. The prevalence of ACM is estimated to range from 1 case in 1,000 persons to 1 case in 5,000, with an average age of diagnosis of approximately 30 years.(1-3) Current treatment options aim to prevent potentially life-threatening arrhythmias and progression to end-stage disease, but they do not target the underlying genetics or disease biology and, as such, patients can continue to experience serious breakthrough events.
공시 • Jun 26+ 1 more updateRenovacor Appoints Wendy Dicicco as the Chief Financial OfficerOn June 3, 2022, the Renovacor, Inc. reported that its Board of Directors (the “Board”) had appointed Wendy DiCicco as the Company’s Chief Financial Officer. Under the CFO Agreement, Ms. DiCicco will provide services to the Company as its Chief Financial Officer in a non-employee capacity, effective as of June 17, 2022 (Effective Date).
공시 • Jun 05+ 1 more updateRenovacor, Inc. Announces CFO ChangesOn May 30, 2022, Fred Driscoll, the Chief Financial Officer of Renovacor, Inc. notified the Company of his decision to resign effective as of June 17, 2022 (the “Effective Date”). Mr. Driscoll resigned for personal reasons and not as a result of any disagreement with the Company or its independent registered public accountants on any matter relating to the Company’s financial or accounting operations, policies or practices. On June 2, 2022, the Board of Directors (the “Board”) of the Company appointed Wendy DiCicco, the Company’s former Interim Chief Financial Officer, as Chief Financial Officer, effective as of the Effective Date. Ms. DiCicco will assume the duties of the principal financial officer of the Company as of the Effective Date. Ms. DiCicco served as the Company’s Interim Chief Financial Officer from September 2019 to March 2022, after which she continued to serve in a consulting capacity. In addition, since November 2018 she has served as an executive board advisory consultant for Board Advantage, LLC. Prior to this time, she was the Chief Operating and Financial Officer of Centinel Spine from August 2017 to October 2018. She previously served as President and Chief Operating Officer of Camber Spine Technologies from November 2014 to July 2017, and has held Chief Financial Officer roles at Nuron Biotech, Quench USA, Globus Medical and Kensey Nash Corporation. Ms. DiCicco has served on the boards of directors of SWK Holdings since February 2022, Sincerus Pharmaceuticals since July 2021, Imvax, Inc. since July 2020, ExpressCells since March 2020 and EyePoint Pharmaceuticals since July 2019. She previously served on the boards of directors of II-VI, Inc. from 2006 until August 2017 as well as the boards of CannaPharma Rx and Syncardia Systems. Ms. DiCicco received a B.S. in accounting from Philadelphia College of Textiles and Science and is a licensed CPA.
공시 • Jun 02Renovacor Announces Data from Pilot Pig Study Showing Successful Cardiac Transduction with REN-001 Delivered Via Low-Dose Retrograde Coronary Sinus Infusion Published in Journal of the American College of CardiologyRenovacor, Inc. announced the publication of the results of a preclinical study demonstrating cardiac transduction with low-doses of REN-001 delivered via retrograde coronary sinus infusion (RCSI) in healthy Yucatan pigs. REN-001 is an AAV-based gene therapy designed to directly address the underlying cause of BAG3-associated dilated cardiomyopathy (BAG3-DCM) by using a validated AAV9 capsid to deliver a functional copy of the BAG3 gene to cardiac tissue. In the pilot Yucatan pig study featured in JACC: BTS, low doses (<1e13 vector genome (vg) per kilogram (kg)) of REN-001 delivered locally to the heart using RCSI resulted in each evaluated cardiomyocyte containing, on average, at least one copy of the delivered BAG3 gene (i.e., vector copy number threshold =1). The study also demonstrated diffuse transduction patterns across multiple regions of the heart and documented the presence of vector mRNA /transcript. Additionally, all animals tolerated the procedure without evidence of heart injury (e.g., arrythmia, presence of myocardial scar, or coronary sinus injury at necropsy). The pilot Yucatan pig study published in JACC: BTS included three dose groups. Group A evaluated a 1.46e12 vg/kg dose, Group B evaluated a 3.45e12 vg/kg dose and Group C evaluated a 7.58e12 vg/kg dose (based on median pig weights for each group). Levels of vector genomes and corresponding RNA transcripts were quantified.
Board Change • Apr 27High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공시 • Apr 15Renovacor, Inc., Annual General Meeting, May 25, 2022Renovacor, Inc., Annual General Meeting, May 25, 2022, at 09:00 US Eastern Standard Time. Agenda: To elect three director nominees that are set forth in the attached 2022 Annual Meeting Proxy Statement, or the Proxy Statement, to serve as Class I directors, whose term will expire in 2025; to ratify the appointment of Ernst & Young LLP, or EY, as independent registered public accounting firm for the 2022 fiscal year; and to transact any other matters that may properly be brought before the Annual Meeting or any adjournment or postponement thereof.
공시 • Mar 29Renovacor, Inc. Appoints Fred Driscoll as Chief Financial OfficerRenovacor, Inc. announced the appointment of Fred Driscoll as Chief Financial Officer (CFO). Mr. Driscoll joins Renovacor with over 25 years of executive experience in the biotech industry. He most recently served as the CFO of Flexion Therapeutics (Flexion), where he led the company through a successful $75 million initial public offering in 2014 and subsequently raised an additional $450 million in capital for the company.
Board Change • Jan 01High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Chairman, President & CEO Magdalene Cook was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Board Change • Sep 07No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Member of Scientific Advisory Board & Director Anne Prener was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.